NCT03969134View on ClinicalTrials.gov

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

February 28, 2023

Conditions
Leishmaniasis, Cutaneous
Interventions
BIOLOGICAL

ChAd63-KH

The vaccine will be injected intramuscularly into the arm.

OTHER

Placebo

The placebo will be injected intramuscularly into the arm.

Trial Locations (1)

Unknown

Institute of Tropical Medicine, Doka

All Listed Sponsors
lead

University of York

OTHER

NCT03969134 - A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL | Biotech Hunter | Biotech Hunter